Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ficus hirta Vahl, also known as 'Wuzhi Maotao', is a traditional botanical drug and medicinal plant belonging to the Moraceae family. It has been utilized for centuries in traditional Chinese medicine and other Asian medical systems to treat a variety of ailments, including indigestion, respiratory conditions (such as cough, asthma, and pneumonia), liver diseases, and inflammatory disorders like arthritis. The plant extract contains a complex mixture of bioactive metabolites, primarily flavonoids, phenylpropanoids, and terpenoids. These components contribute to its diverse pharmacological profile, which includes immune-modulating, anti-inflammatory, antioxidant, and hepatoprotective activities. Notably, research has identified CD36 as a key biological target through which Ficus hirta Vahl regulates lipid metabolism and inflammation, particularly in the context of non-alcoholic fatty liver disease (NAFLD). Toxicological assessments have confirmed the safety and non-toxicity of the extract for medicinal use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ficus hirta vahl.